Sulbactam sodium is a competitive, irreversible beta-lactamase inhibitor. Its binding to penicillin-binding proteins imparts weak intrinsic antibacterial activity[2]. Ampicillin-Sulbactam has a wide range of antibacterial activity that includes Gram-positive and Gram-negative aerobic and anaerobic bacteria[3]. The sulbactam/ampicillin combination has been approved for the treatment of adults with intraabdominal, skin and skin structure, and gynecological infections. Clinical studies to date have also shown the combination to be effective for the treatment of meningitis, pneumonia, gonorrhea, epiglottis, urinary tract infections, cervical adenitis, and as prophylaxis for abdominal and gynecological surgeries[4].
Sulbactam Sodium/舒巴坦钠 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
Male high alcohol drinking (HAD1) rats
High alcohol drinking rat model
Intraperitoneal injection
100 and 200 mg/kg
Five consecutive days
To evaluate the effects of sulbactam on ethanol consumption and its effects on GLT-1 and NMDA receptor subtypes (NR2A and NR2B) in the Acb core (AcbCo) and Acb shell (AcbSh). It was found that sulbactam at both doses attenuated ethanol consumption and restored ethanol-decreased GLT-1 and NR2B expression. Moreover, sulbactam (200 mg/kg) reduced ethanol-increased high mobility group box 1 (HMGB1) and receptor for advanced glycation end-products (RAGE) expression.
搜索
